There is strong evidence from controlled clinical trials that in the setting of acute myocardial
infarction complicated by heart failure or isolated left ventricular dysfunction, angiotensin …

A number of therapies are beneficial in the management of patients with acute myocardial
infarction (MI), including revascularization with either percutaneous coronary intervention or …

Angiotensin‐converting enzyme inhibitor therapy has been shown to be effective in treating
patients across the spectrum of cardiac disease. Utility has been demonstrated for both …

It has been established from multiple randomised, placebo-controlled trials that angiotensin-
converting enzyme inhibitors reduce the risk of death and major non-fatal cardiovascular …

Coronary artery diseases (CADs) are preventable and controllable disorders, but they
continue to be a major cause of morbidity and premature mortality across globe. India is …

Which patients with an acute myocardial infarction should be treated with an angiotensin-
converting enzyme (ACE) inhibitor and when should this treatment be initiated? Combining …

Angiotensin-converting enzyme (ACE) inhibitors are now established drugs in the treatment
of hypertension and heart failure. However, their use in patients after a myocardial infarction …

A number of major studies have examined the impact of angiotensin-converting enzyme
inhibitors on mortality in patients with ischemic heart disease. However, in these studies …

Following acute myocardial infarction, patients are at increased risk of developing heart
failure, which is more prevalent in those with reduced ventricular systolic function. Activation …

Approximately 50% of patients recovering from acute myocardial infarction have significant
left ventricular systolic dysfunction and could benefit considerably from the long-term …